El-Gamal, Mohammed I. Oh, Chang-Hyun 2024-01-20T14:34:44Z 2024-01-20T14:34:44Z 2022-01-10 2012-05-20 0253-2964 https://pubs.kist.re.kr/handle/201004/129243 A diarylurea compound 1 possessing pyrrolo[3,2-c]pyridine nucleus was designed and synthesized with structure similarity to Sorafenib. Compound 1 was tested over 60-cancer cell line panel at a single dose concentration of 10 mu M and showed high activity. It was further tested in a five-dose mode to determine its IC50, TGI, and LC50 values over the 60 cell lines. Compound 1 showed high potency and good efficacy, and was accordingly tested at a single dose concentration of 10 mu M over a panel of 40 kinases. At this concentration, it completely inhibited the enzymatic activities of a number of oncogenic kinases, including ABL, ALK, c-RAF, FLT3, KDR, and TrkB. The target compound was subsequently tested over these 6 kinases in 10-dose testing mode in order to determine its IC50 values. English KOREAN CHEMICAL SOC ANAPLASTIC LYMPHOMA KINASE EML4-ALK FUSION GENE CELL LUNG-CANCER THERAPEUTIC TARGET TYROSINE KINASE ALZHEIMERS-DISEASE NEUROBLASTOMA MUTATIONS MELANOMA RECEPTOR Design and Synthesis of an Anticancer Diarylurea Derivative with Multiple-Kinase Inhibitory Effect Article 10.5012/bkcs.2012.33.5.1571 1 BULLETIN OF THE KOREAN CHEMICAL SOCIETY, v.33, no.5, pp.1571 - 1576 BULLETIN OF THE KOREAN CHEMICAL SOCIETY 33 5 1571 1576 scie scopus kci 000304432100025 2-s2.0-84861368054 Chemistry, Multidisciplinary Chemistry Article ANAPLASTIC LYMPHOMA KINASE EML4-ALK FUSION GENE CELL LUNG-CANCER THERAPEUTIC TARGET TYROSINE KINASE ALZHEIMERS-DISEASE NEUROBLASTOMA MUTATIONS MELANOMA RECEPTOR Anticancer Diarylurea Multiple-kinase Pyrrolo[3,2-c]pyridine